Investment Thesis
CERUS demonstrates solid 16.1% YoY revenue growth in the medical devices sector, but this is fundamentally undermined by negative operating profitability (-0.7% margin), significant operating cash burn (-$3.0M), and elevated leverage (1.26x D/E) with inability to cover interest expenses. The combination of revenue growth without operational cash generation or profitability suggests the business model is not viable at current scale.
Strengths
- Strong YoY revenue growth of 16.1% indicates market demand for products
- Gross margin of 26% demonstrates viable product economics and pricing power
- Adequate short-term liquidity with 1.63x current ratio provides near-term runway
Risks
- Negative operating cash flow of -$3.0M annually signals cash burn despite top-line growth
- High debt-to-equity ratio of 1.26x combined with negative interest coverage (-0.1x) creates unsustainable capital structure
- Unprofitable operations with -3.1% net margin and negative returns on capital (ROE: -2.4%, ROA: -0.7%)
Key Metrics to Watch
- Operating cash flow trend - must achieve positive OCF for sustainability
- Operating margin trajectory - path to break-even criticality
- Debt service capability and debt reduction progress
Financial Metrics
Revenue
53.7M
Net Income
-1.6M
EPS (Diluted)
$-0.01
Free Cash Flow
-3.3M
Total Assets
222.9M
Cash
27.9M
Profitability Ratios
Gross Margin
26.0%
Operating Margin
-0.7%
Net Margin
-3.1%
ROE
-2.4%
ROA
-0.7%
FCF Margin
-6.1%
Balance Sheet & Liquidity
Current Ratio
1.63x
Quick Ratio
1.06x
Debt/Equity
1.26x
Debt/Assets
69.4%
Interest Coverage
-0.08x
Long-term Debt
84.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T17:12:40.359179 |
Data as of: 2026-03-31 |
Powered by Claude AI